Literature DB >> 15331719

A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity.

Kenji Someya1, Ke-Qin Xin, Kazuhiro Matsuo, Kenji Okuda, Naoki Yamamoto, Mitsuo Honda.   

Abstract

To evaluate immunity induced by a novel DNA prime-boost regimen, we constructed a DNA plasmid encoding the gag and pol genes from simian immunodeficiency virus (SIV) (SIVgag/pol DNA), in addition to a replication-deficient vaccinia virus strain DIs recombinant expressing SIV gag and pol genes (rDIsSIVgag/pol). In mice, priming with SIVgag/pol DNA, followed by rDIsSIVgag/pol induced an SIV-specific lymphoproliferative response that was mediated by a CD4+-T-lymphocyte subset. Immunization with either vaccine alone was insufficient to induce high levels of proliferation or Th1 responses in the animals. The prime-boost regimen also induced SIV Gag-specific cellular responses based on gamma interferon secretion, as well as cytotoxic-T-lymphocyte responses. Thus, the regimen of DNA priming and recombinant DIs boosting induced Th1-type cell-mediated immunity, which was associated with resistance to viral challenge with wild-type vaccinia virus expressing SIVgag/pol, suggesting that this new regimen may hold promise as a safe and effective vaccine against human immunodeficiency virus type 1. Copyright 2004 American Society for Microbiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15331719      PMCID: PMC515009          DOI: 10.1128/JVI.78.18.9842-9853.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses.

Authors:  Jianming Qiu; Ramnath Nayak; Gregory E Tullis; David J Pintel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 3.  Immunological aspects of Epstein-Barr virus infection.

Authors:  Shouichi Ohga; Akihiko Nomura; Hidetoshi Takada; Toshiro Hara
Journal:  Crit Rev Oncol Hematol       Date:  2002-12       Impact factor: 6.312

4.  Structural analysis of vaccinia virus DIs strain: application as a new replication-deficient viral vector.

Authors:  Koji Ishii; Yoshiaki Ueda; Kazuhiro Matsuo; Yoshiharu Matsuura; Takashi Kitamura; Kenzo Kato; Yasuyuki Izumi; Kenji Someya; Takeaki Ohsu; Mitsuo Honda; Tatsuo Miyamura
Journal:  Virology       Date:  2002-10-25       Impact factor: 3.616

Review 5.  A review of vaccines for HIV prevention.

Authors:  Matilu Mwau; Andrew J McMichael
Journal:  J Gene Med       Date:  2003-01       Impact factor: 4.565

Review 6.  Cytokines in experimental herpes simplex virus infection.

Authors:  Veijo Hukkanen; Eeva Broberg; Aimo Salmi; Juha-Pekka Erälinna
Journal:  Int Rev Immunol       Date:  2002 Jul-Oct       Impact factor: 5.311

7.  Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination.

Authors:  Jamal Baig; Daniel B Levy; Paul F McKay; Joern E Schmitz; Sampa Santra; Ramu A Subbramanian; Marcelo J Kuroda; Michelle A Lifton; Darci A Gorgone; Linda S Wyatt; Bernard Moss; Yue Huang; Bimal K Chakrabarti; Ling Xu; Wing-Pui Kong; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Angela Carville; Andrew A Lackner; Ronald S Veazey; Norman L Letvin
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts.

Authors:  P Putkonen; M Quesada-Rolander; A C Leandersson; S Schwartz; R Thorstensson; K Okuda; B Wahren; J Hinkula
Journal:  Virology       Date:  1998-10-25       Impact factor: 3.616

9.  Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection.

Authors:  O Pontesilli; M R Klein; S R Kerkhof-Garde; N G Pakker; F de Wolf; H Schuitemaker; F Miedema
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

10.  HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.

Authors:  Gaku Sakaue; Takachika Hiroi; Yoko Nakagawa; Kenji Someya; Kohich Iwatani; Yoshiki Sawa; Hidemi Takahashi; Mitsuo Honda; Jun Kunisawa; Hiroshi Kiyono
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

View more
  12 in total

1.  Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.

Authors:  Monika Simmons; Kevin R Porter; Curtis G Hayes; David W Vaughn; Robert Putnak
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.

Authors:  Masaru Kanekiyo; Kazuhiro Matsuo; Makiko Hamatake; Takaichi Hamano; Takeaki Ohsu; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Atsuhiko Hasegawa; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Authors:  Kenji Someya; Dayaraj Cecilia; Yasushi Ami; Tadashi Nakasone; Kazuhiro Matsuo; Sherri Burda; Hiroshi Yamamoto; Naoto Yoshino; Masahiko Kaizu; Shuji Ando; Kenji Okuda; Susan Zolla-Pazner; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif.

Authors:  Yasuyuki Eda; Mari Takizawa; Toshio Murakami; Hiroaki Maeda; Kazuhiko Kimachi; Hiroshi Yonemura; Satoshi Koyanagi; Kouichi Shiosaki; Hirofumi Higuchi; Keiichi Makizumi; Toshihiro Nakashima; Kiyoshi Osatomi; Sachio Tokiyoshi; Shuzo Matsushita; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Biodistribution and immunity of adenovirus 5/35 and modified vaccinia Ankara vector vaccines against human immunodeficiency virus 1 clade C.

Authors:  Masaru Shimada; Haibin Wang; Motohide Ichino; Takehiro Ura; Nobuhisa Mizuki; Kenji Okuda
Journal:  Gene Ther       Date:  2022-01-06       Impact factor: 5.250

7.  Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.

Authors:  M Shimada; H-B Wang; A Kondo; X-P Xu; A Yoshida; K Shinoda; T Ura; H Mizuguchi; D Klinman; J-L Luo; H Bai; K Okuda
Journal:  Gene Ther       Date:  2008-10-16       Impact factor: 5.250

Review 8.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

9.  Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.

Authors:  Kazuhiro Matsuo; Yasuhiro Yasutomi
Journal:  Tuberc Res Treat       Date:  2011-05-24

10.  HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.

Authors:  Tsungai Ivai Jongwe; Ros Chapman; Nicola Douglass; Shivan Chetty; Gerald Chege; Anna-Lise Williamson
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.